A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Inclusion Criteria: 1. Subjects must voluntarily agree to participate in the trial and sign a written informed consent form; 2. ≥18 years of age, either sex; 3. Previous pathological biopsy was diagnosed as intermediate or high-risk NMIBC ; 4. ECOG performance status of 0-1; 5. Life expectancy ≥ 2 years; 6. Adequate bone marrow and organ function. Exclusion Criteria: 1. Received TURBT or other surgical treatment or radiotherapy for bladder lesions within 2 weeks before the first administration; 2. Patients who were receiving treatment in other clinical trials or less than 4 weeks from the end of the first administration in this study; 3. History of serious cardiovascular and cerebrovascular diseases; 4. Severe infection within 2 weeks prior to the first dose; 5. Adverse reactions of previous anti-tumor treatment have not recovered to Grade ≤ 1 per NCI-CTCAE v5.0; 6. Oversize surgery or severe trauma within 4 weeks before the first use of research drugs; 7. Previously received any TNFR agonist antibody therapy, such as OX40, CD137, CD27, CD357 antibodies.